PREPARE-IT-2 Trial Shows Use of IPE Fails to Reduce COVID-19 Hospitalization and Death

PREPARE-IT-2 Trial Shows Use of IPE Fails to Reduce COVID-19 Hospitalization and Death

The pharmaceutical industry is abuzz with competition surrounding the emergence of a market for COVID-19 therapeutics. The result is countless trials and therapies, with each company working towards a spot in this newfound economy. One of those trials was PREPARE-IT 2. Recently, it was announced that the PREPARE-IT 2 (Prevention and Treatment of COVID-19 With EPA in Subjects at Risk – Intervention Trial 2) study, sponsored by Amarin Pharma, Inc., showed that the use of icosapent ethyl (IPE) for 28 days did not reduce COVID-19–related hospitalizations or mortality among patients with non hospitalized SARS-CoV-2 infection. 

The results of this study were presented by Dr. Rafael Diaz at the American Heart Association Virtual Annual Scientific Sessions (AHA 2021), November 15, 2021.

What is IPE?

Icosapent ethyl also known as Ethyl eicosapentaenoic acid is sold under the brand name of Vascepa and other as a medication used to treat dyslipidemia and hypertriglyceridemia. This treatment is utilized in combination with modification to diet in adults with hypertriglyceridemia  ≥  ≥ 150 mg/dL.

The drug is produced from omega-3 fatty acid eicosapentaenoic acid (EPA...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee